RVTY Stock Analysis — Revvity
Sector: Healthcare
AI Verdict
Revvity trades at 15.6x next year's earnings while analysts expect +82.5% EPS growth — that's cheap for the growth you're getting if their proprietary assay moat holds up.
Competitive Moat
Revvity specializes in life sciences and diagnostics, with a defensible position built on proprietary assay technologies and a broad installed base in lab instrumentation. Their deep integration into research workflows and recurring consumables revenue make it difficult for labs to switch suppliers.
Summary
Revvity is notable right now for its expected 82.5% jump in earnings over the next year, far outpacing its sector.
Where It Stands
Revvity has delivered a 0.76% return over the past year, trades at 15.6x next year’s earnings versus a healthcare median of 22x, and its RSI of 63.3 signals neutral-to-elevated momentum.
Key Metrics
- RSI: 63.3 — Near Overbought
- Trailing P/E: 28.4x
- Forward P/E: 15.6x
- PEG Ratio: 0.34
- Earnings Growth: +0.8%
- Revenue Growth: +0.0%
- Market Cap: $10.5B
- Dividend Yield: 0.00%
- 1-Year Return: 0.76%
- 52-Week High: $118.30
- 52-Week Low: $81.22
Analyst Consensus
14 Buy · 11 Hold · 0 Sell (25 analysts)
Bull Case
With analysts forecasting 82.5% EPS growth and a forward P/E of 15.6x, you’re getting rapid earnings growth at a discount to the sector median.
Bear Case
If the P/E reverts from 28.4x trailing to the sector median of 22x without the forecasted growth materializing, the stock could see a 22% valuation drop.
Catalyst to Watch
Watch for upcoming earnings releases — if the company confirms the 82.5% EPS growth, the valuation case strengthens.